FDA observations not to affect supply: Lupin

MUMBAI: Drug major Lupin on Friday said supply of products manufactured at its Mandideep facility will not be affected despite the US Food and Drug Administration (USFDA) listing as many as 15 observations to be addressed after inspecting the plant.

���The outcome of this inspection does not affect the supply of products manufactured at this facility across the world, or the approvability of pending applications with the USFDA,��� the company said in a filing to the BSE. The USFDA had inspected the manufacturing plant as a part of ���routine Good Manufacturing Practice,��� the company said. An inspection report was issued listing 15 inspectional observations.